PCI Biotech Holding Extends Preclinical Research Collaboration

Jan 18 (Reuters) - PCI BIOTECH HOLDING ASA:
* EXTENDING PRECLINICAL RESEARCH COLLABORATION WITH UNDISCLOSED TOP-10 PHARMA COMPANY, INITIATED IN SEPTEMBER 2015​
* WILL EVALUATE DATA GENERATED AND EXPLORE POTENTIAL FOR FURTHER PARTNERSHIP BASED ON OUTCOME
* - EXTENDED EVALUATION PERIOD SPANS OVER 6 MONTHS, UNTIL THE END OF JUNE 2018, AND MAY BE FURTHER EXTENDED Source text for Eikon: Further company coverage:

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

Gdynia Newsroom

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Purchase Licensing Rights